IP Library Patent Application 13089029
Patent Application
App. No. 13/089,029

TREATMENT OF LEG ULCERS USING PLACENTA DERIVED COLLAGEN BIOFABRIC

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/089,029
Abstract

The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of a leg ulcer.

Claims (24)

1 . A method of treating a leg ulcer, comprising contacting said ulcer with a collagen biofabric, wherein said contacting improves at least one aspect of the leg ulcer, or prevents or reduces the worsening of at least one aspect of a leg ulcer.

2 . The method of claim 1 , wherein said collagen biofabric is not artificially crosslinked.

3 . The method of claim 1 , wherein said collagen biofabric is about 20% or less water by weight.

4 . The method of claim 1 , wherein said collagen biofabric is not protease-treated during production.

5 . The method of claim 1 , wherein said contacting is for a time sufficient for at least one aspect of the leg ulcer to measurably improve compared to a leg ulcer not contacted with the collagen biofabric.

6 . The method of claim 1 , wherein said contacting is for a time sufficient to prevent or reduce the worsening of at least one aspect of a leg ulcer.

7 . The method of claim 1 , wherein said leg ulcer is a venous leg ulcer, arterial leg ulcer, diabetic leg ulcer or decubitus ulcer.

8 . The method of claim 1 , wherein said leg ulcer is a venous leg ulcer.

9 . The method of claim 1 , wherein said collagen biofabric is provided as a sheet or membrane.

10 . The method of claim 1 , wherein said collagen biofabric is provided as a netting or webbing.

11 . The method of claim 1 , wherein said collagen biofabric is mounted on a support.

12 . The method of claim 11 , wherein said support is a bandage.

13 . The method of claim 1 , wherein said contacting comprises placing the collagen biofabric on the leg ulcer so that substantially all of the surface area of the biofabric contacts the leg ulcer.

14 . The method of claim 1 , wherein said collagen biofabric additionally comprises a bioactive compound not naturally-occurring in the collagen biofabric, or present in a different concentration than in collagen biofabric to which the bioactive compound has not been added.

15 . The method of claim 14 , wherein said bioactive compound is a small organic molecule, an antibiotic, pain medication, anti-inflammatory agent, cytokine, growth factor, enzyme inhibitor, kinase inhibitor, an anti-tumor agent, an anti-fungal agent, an anti-viral agent, an anti-infective agent, a wound sealant or a wound healing or sealing agent.

16 . The method of claim 15 , wherein said wound healing or sealing agent is platelet-derived growth factor (PDGF), transforming growth factor (TGF), thymosin, hyaluronic acid, fibrin, fibronectin or thrombin, or a combination thereof.

17 . A kit for the facilitation of the treatment of leg ulcers, comprising a piece of collagen biofabric.

18 . The kit of claim 17 further comprising a medical device, disposable or drug that facilitates treatment of a leg ulcer.

19 . The kit of claim 17 , wherein the piece of collagen biofabric is provided as a single sheet or patch in a sterile container or wrapping.

20 . The kit of claim 17 further comprising two or more pieces of collagen biofabric, separately wrapped or contained.

21 . The kit of claim 17 further comprising a support for the collagen biofabric.

22 . The kit of claim 17 further comprising an anti-infective agent.

23 . The kit of claim 17 , further comprising a wound healing agent.

24 . The kit of claim 17 , wherein said collagen biofabric is provided as a sheet in a sterile double-peel pouch.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2023
From: CLARITY ACQUISITION II LLC
To: CELULARITY INC.
Reel/Frame 062881/0570 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2012
From: HARIRI, ROBERT; SMIELL, JANICE
To: ANTHROGENESIS CORPORATION
Reel/Frame 027832/0229 →